Article Details

Wells Fargo & Company Lowers Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $1.50

Retrieved on: 2025-03-23 05:17:21

Tags for this article:

Click the tags to see associated articles and topics

Wells Fargo & Company Lowers Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $1.50. View article details on hiswai:

Excerpt

Two Sigma Investments LP now owns 76,347 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 19,146 shares during ...

Article found on: www.defenseworld.net

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo